Phase II study of Bevacizumab + Pemetrexed in elderly patients with advanced non-squamous non-small-cell lung cancer
Phase 2
- Conditions
- onsquamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000010733
- Lead Sponsor
- Central Japan Lung Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Not provided
Exclusion Criteria
1) symptomatic brain metastasis 2) History of hemoptysis with 2.5mL or more 3) severe comorbidity (cardiovascular disease, pulmonary fibrosis/interstitial pneumonia, tendency to hemorrhages, uncontrolled hypertension or diabetes) 4) History of active double cancer within 5 years. 5) uncontrolled retention of fluid 6)receiving more than two anticoagulant drugs 7) active gastrointestinal bleeding or intraperitoneal inflammation 8) other inadequacy cases judged by attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Safety, Disease Control Rate (DCR), Response rate (RR), Overall Survival (OS), Quality of life (QOL), Exploration of biomarkers, Side effect prediction using the laboratory data